Landmark Infrastructure Partners LP Announces Cash Distributions for its Series B and Series C Preferred Units

EL SEGUNDO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Landmark Infrastructure Partners LP (the “Partnership”) (NASDAQ: LMRK) announced today that the board of directors of its general partner (the “Board”) declared a quarterly cash distribution for its 7.90% Series B Cumulative Redeemable Perpetual Preferred Units (the “Series B Preferred Units”) (NASDAQ: LMRKO) of $0.49375 per Series B Preferred Unit, payable on February 16, 2021, to Series B Preferred Unitholders of record as of February 1, 2021.  

The Board also declared a quarterly cash distribution for the Series C Floating-to-Fixed Rate Cumulative Perpetual Redeemable Convertible Preferred Units (the “Series C Preferred Units”) (NASDAQ: LMRKN) of $0.4375 per Series C Preferred Unit, payable on February 16, 2021, to Series C Preferred Unitholders of record as of February 1, 2021. The quarterly distribution of $0.4375 per Series C Preferred Unit is based on the distribution rate calculation equal to the greater of (i) 7.00% per annum, and (ii) an annual floating rate of the three-month LIBOR on the distribution determination date of November 12, 2020 plus a spread of 4.698% per annum.

About Landmark Infrastructure Partners LP
The Partnership owns and manages a portfolio of real property interests and infrastructure assets that the Partnership leases to companies in the wireless communication, outdoor advertising, renewable power generation and digital infrastructure industries. 

Notice

This release serves as qualified notice to nominees as provided for under Treasury Regulation Section 1.1446-4(b)(4) and (d).  Please note that we believe that zero percent of the Partnership’s distributions to foreign investors are attributable to income that is effectively connected with a United States trade or business, and we believe that 100 percent is attributable to dividend income from a real estate investment trust subject to withholding under Internal Revenue Code Section 1441.  Nominees, and not the Partnership, are treated as withholding agents responsible for withholding distributions received by them on behalf of foreign investors.

The distributions consist of the following components:


Series B Preferred Units
 
Effectively Connected Income $0.00
U.S. Dividend Income from REIT $0.49375
   

Series C Preferred Units
 
Effectively Connected Income  $0.00
U.S. Dividend Income from REIT $0.4375

Cautionary Note Regarding Forward Looking Statements
Disclosures in this press release contain certain forward-looking statements within the meaning of the federal securities laws. Statements that do not relate strictly to historical or current facts are forward-looking. These statements contain words such as “possible,” “if,” “will,” “expect” and “assuming” and involve risks and uncertainties including, among others that our business plans may change as circumstances warrant. Accordingly, readers should not place undue reliance on forward-looking statements as a prediction of actual results. For more information concerning factors that could cause actual results to differ materially from those conveyed in the forward-looking statements, please refer to the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC. Any forward-looking statements in this press release are made as of the date of this press release and the Partnership undertakes no obligation to update or revise such forward-looking statements to reflect events or circumstances that occur, or of which the Partnership becomes aware, after the date hereof, unless required by law.

CONTACT:     Marcelo Choi
      Vice President, Investor Relations
      (213) 788-4528
      [email protected]



Regency Centers Announces Tax Information for 2020 Distributions

JACKSONVILLE, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) — Regency Centers Corporation (The “Company”) (NASDAQ:REG) today announced the federal income tax treatment of its 2020 distributions to holders of its common stock.

Regency Centers Corporation Common Stock: Symbol REG CUSIP #: 758849103

Record Date Payable Date Total Distribution Per Share Distribution Allocated to 2020 Ordinary Dividends Total Capital Gain Distr. Unrecapt Section 1250 Gain

(1)
Nontaxable Distributions Section 199A Dividends

(2)
                 
2/24/2020 3/5/2020 $0.5950 $0.5950 $0.5950 $0.0000 $0.0000 $0.0000 $0.5950
5/18/2020 5/26/2020 $0.5950 $0.5950 $0.5950 $0.0000 $0.0000 $0.0000 $0.5950
8/14/2020 8/24/2020 $0.5950 $0.5950 $0.5950 $0.0000 $0.0000 $0.0000 $0.5950
12/16/2020 1/5/2021 $0.5950 $0.4050 $0.4050 $0.0000 $0.0000 $0.0000 $0.4050
                 
TOTALS   $
2.3800
$
2.1900
$
2.1900
$
0.0000
$
0.0000
$
0.0000
$
2.1900

  (1) This is the amount included in the Total Capital Gain Distribution that is Unrecaptured Section 1250 gain.
  (2) This amount represents dividends eligible for the 20% qualified business income deduction under Section 199A, and is included in Ordinary Dividends.

Please note, of the $0.5950 per share dividend declared for holders of record on December 16, 2020 and paid on January 5, 2021, $0.4050 is reported for income tax purposes in 2020 with the remaining $0.1900 to be reported in 2021.

This information is being provided to assist shareholders with tax reporting related to distributions made by the Company. Taxability of 2020 distributions is not necessarily indicative of taxability of future distributions. The tax information provided herein should not be construed as tax advice and shareholders are encouraged to consult with their tax advisors as to their specific tax treatment of the Company’s distributions.

About Regency Centers Corporation (NASDAQ: REG)

Regency Centers is the preeminent national owner, operator, and developer of shopping centers located in affluent and densely populated trade areas. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member. For more information, please visit RegencyCenters.com.

Christy McElroy
904 598 7616
[email protected]



AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients

DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the first two patients have been dosed in the Phase 2b OPTION 2 extension study of MS1819 using immediate release capsules for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

The company recently announced an additional study arm in the Phase 2b OPTION 2 study utilizing immediate release capsules in efforts to identify the optimal dose and delivery method of MS1819. The OPTION 2 extension phase design will test patients 18 years or older, who have already completed the OPTION 2 crossover trial, at higher doses relative to the previously conducted OPTION 1 trial. As of today, two patients have been dosed and will continue to be treated for the duration of the next two weeks.

“As expected, the Data Monitoring Committee (DMC) remains supportive of our program with no safety concerns regarding the design and protocol of the study,” said Dr. James Pennington, Chief Medical Officer of AzurRx BioPharma. “Due to enrollment in the initial crossover trial being ahead of schedule, we are given an opportunity to thoroughly explore optimal doses and capsule types that will help guide our future development plans for MS1819 in a Phase 3 program. In the meantime, we will continue our preparation for a successful FDA meeting later this year.”

Topline data results for this study are anticipated in Q1 2021, as enrollment remains strong.

About MS1819

MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. MS1819, supplied as an oral non-systemic biologic capsule, is derived from the Yarrowia lipolytica yeast lipase and breaks up fat molecules in the digestive tract of EPI patients so that they can be absorbed as nutrients. Unlike the standard of care, porcine pancreatic enzyme replacement therapy (PERT), the MS1819 synthetic lipase does not contain any animal products.

The global market for PERT was estimated to be approximately $1.4 billion in the U.S. and over $2 billion globally in 2019. There currently is no non-animal based enzyme replacement therapy in the market for the treatment of exocrine pancreatic insufficiency. AzurRx believes that MS1819 has the potential to provide a safe and effective non-animal derived, or synthetic, alternative to PERT, without the risk of animal pathogen transmission or fibrosing colonpathy. In addition, we believe that MS1819 has the potential to improve patient compliance and quality of life given anticipated reductions in pill burden and pill size relative to PERT.

About Exocrine Pancreatic Insufficiency

EPI is a condition characterized by deficiency of the exocrine pancreatic enzymes, resulting in a patient’s inability to digest food properly, or maldigestion. The deficiency in this enzyme can be responsible for greasy diarrhea, fecal urge and weight loss.

There are more than 30,000 patients in the U.S. with EPI caused by cystic fibrosis according to the Cystic Fibrosis Foundation and approximately 90,000 patients in the U.S. with EPI caused by chronic pancreatitis according to the National Pancreas Foundation. Patients are currently treated with porcine pancreatic enzyme replacement pills.

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company has a pipeline of three gut-restricted GI clinical programs. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-420, for grade 1 Immune Checkpoint Inhibitor-Associated Colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information visit www.azurrx.com.

Forward-Looking Statements

This press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial; and the Company’s success in raising additional financing to support its operations. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Company’s financial results, including those related to the clinical development of MS1819, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Company’s operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 under the heading “Risk Factors,” as well as the Company’s subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.


For more information:

AzurRx BioPharma, Inc.
1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445
Phone: (646) 699-7855
[email protected] 

Investor Relations contact:

LifeSci Advisors, LLC. 
Hans Vitzthum, Managing Director 
1 International Place, Suite 1480 
Boston, MA 02110 
Phone: (617) 430-7578 
[email protected] 



New integration between Tealium and Agillic enhances the value of customer data

Press release, Copenhagen 21 January 2021

US-based


Tealium


has developed a standard connector to Danish omnichannel marketing software company Agillic. With the connector, clients using


Tealium


, a Customer Data Platform (CDP), and Agillic can more easily create and execute highly personalised communication based on data from many disparate sources.

With the standard connector, the synergy between the Tealium Customer Data Platform and Agillic enhances the capacity and intelligence of both systems, enabling a more personalised communication, which is recognised as impacting conversion rates and boosting the value of the marketing communication significantly.

The standard connector substitutes a custom webhook and enables smoother data exchange between the Tealium CDP and the Agillic Platform. As the CDP collects vital data from many sources, it calculates, for example, which message or offer a given customer is most likely to respond to. However, it doesn’t have an omnichannel execution capacity, which is why it makes sense to integrate to the Agillic Platform. In the Agillic Platform, data from the CDP is automatically mapped up against the customer profiles, and the most relevant content can be delivered to the consumers.

Point-and-click integration developed with Solution Partner eCapacity

Agillic’s Solution Partner eCapacity and Tealium collaborated to create the connector. Martin Wammen, Partner MarTech and Business Development at eCapacity, says: “We had a client request for the connector and reached out to Tealium. Together we developed a powerful point-and-click integration, which means the two systems can be integrated extremely fast and effectively, within hours.”

An increasing need for integrations

When a company has a best-of-breed approach, i.e. build their MarTech stack of a series of highly specialised software components, it requires integrations to tie the systems together.

Emre Gürsoy, CEO of Agillic, says: “As high levels of personalisation have become the norm; brands are continually retooling their tech stack to get a complete picture of the customer. No software solution is an island, and CDPs, DMPs and best-of-breeds such as Agillic, are all systems which provide more value when connected. We experience that integration capability is a highly prioritised criterion and the fact that Agillic offers standard integrations to software such as Microsoft CRM, BI and eCommerce systems, and now Tealium gives us a competitive edge.”

 
For further information, please contact 
Emre Gürsoy, CEO, Agillic A/S
+45 3078 4200
[email protected] 

About Tealium
Tealium connects customer data– spanning web, mobile, offline, and IoT devices— so brands can connect with their customers. Tealium empowers companies to create a unified, real-time customer data infrastructure. The Tealium Customer Data Hub encompasses tag management, an API hub, a customer data platform with machine learning, and data management solutions that make customer data more valuable, actionable, and secure. Over 1,000 businesses worldwide trust Tealium to power their customer data strategies. For more information, visit www.tealium.com.

About eCapacity
eCapacity is a prize-winning digital advisory. They help leading brands and companies in the Nordics realise ambitious growth ambitions within industries spanning finance, telcom, retail, media and industry. www.ecapacity.com

About Agillic A/S
Agillic is a Nordic software company enabling marketers to maximise the use of data and translate it into relevant and personalised communication establishing strong relations between people and brands. Our customer marketing platform uses AI to enhance the business value of customer communication. By combining data-driven customer insights with the ability to execute personalised communication, we provide our clients with a head start in the battle of winning markets and customers. 

Besides the company headquarter in Copenhagen, Agillic has sales offices in London (UK), Stockholm (Sweden), as well as a development unit in Kyiv (Ukraine). For further information, please visit www.agillic.com 

Agillic A/S Nasdaq First North Growth Market Copenhagen: AGILC

Masnedøgade 22, Copenhagen Ø – Denmark

                                                                                                                                                

 

Attachment



CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients

EDEN PRAIRIE, Minn., Jan. 21, 2021 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, physician-led webinar to discuss “Real-World Experience Using Ultrafiltration in the Management of Heart Failure Patients.” The virtual event will take place on Wednesday, January 27 at 11 a.m. Central Time.  

The webinar panelists include:

  • Robert A. Watson III, MD, FAAC, Chief, Cardiology Division, Co-Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
  • Donald C. Haas, MD, Medical Director, Ventricular Assist Device Program; Co-Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
  • Maureen Hummel, CRNP, Clinical Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
  • Patti Barrella, MSN, CHFN, Heart Failure Coordinator at Abington Jefferson Health, Pennsylvania
  • John L. Jefferies, Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center

90% of the nearly 1 million annual heart failure hospitalizations in the U.S. are due to signs and symptoms of fluid overload.1,2,Volume regulation and management are key components to the treatment of heart failure patients.3 Mechanical ultrafiltration (UF), such as the Aquadex™ technology, has been used successfully to treat heart failure patients suffering from fluid overload. Data recently published in the Journal of Cardiac Failure Supplement demonstrated UF with Aquadex is a safe and effective strategy for decongestion and compares favorably in reducing heart failure rehospitalizations, renal function response, and weight/volume loss. The panelists from Abington Jefferson Health can provide unique perspective on the data as authors of the study.

Those interested in attending the educational webinar can register through this link. For those unable to attend the webinar, an archive of the webcast will be available within 48 hours after the event concludes on the CHF Solutions’ YouTube channel. and CHF Solutions’ website.

1.
Costanzo MR, et al. J Am Coll
Cardiol
. 2007 Feb 13; 49(6): 675-683.

2. Gheorghiade M, Filippatos G. Eur Heart J. 2005 Mar 15; 7 (Suppl): B13-B19.

3
.
Miller WL. Circ Heart Fail.206;
9:e
002922-31

A
bout CHF Solutions

CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex System

The Aquadex SmartFlow™ system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements

Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the use of Aquadex technology to treat heart failure patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205

Matt Bacso, CFA
Gilmartin Group LLC

MEDIA:

Jessica Stebing
Health+Commerce
260-336-6202



Muscle Maker Grill Aggressively Moves into Direct-to-Consumer Prepared Meal Plan Market

League City, Texas, Jan. 21, 2021 (GLOBE NEWSWIRE) — Muscle Maker, Inc. (Nasdaq: GRIL) the parent company of Muscle Maker Grill, Healthy Joe’s and MMG Burger Bar, a fast-casual concept known for serving “healthier for you” meals, today announced the launch of www.MuscleMakerPrep.com. Starting today, customers can order ready-made “healthier for you” prepared meals shipped directly to their doorstep. The first location to launch this program is located in the Chelsea neighborhood of NYC allowing customers within 250 miles to order their ready-made meals. Additional sites are planned to come on-line throughout Q1 and Q2 increasing the company’s reach to consumers.

Muscle Maker’s strategy continues to focus on non-traditional locations and ways to reach consumers. The company believes the restaurant industry has changed. Being able to reach consumers through multiple touch points is critical to its strategy. Expanding in ready-made, prepared meal plans shipped directly to consumers doorsteps is a new way to get the company’s healthier products into the hands of consumers through contactless delivery and convenience. This new business line expands the company’s reach to consumers and includes brick-and-mortar locations, non-traditional locations such as military bases and universities, home delivery through ghost kitchens and now meal plans shipped via UPS direct to consumers. This model can work out of all existing locations, including ghost kitchens and will be offered to sell through franchise locations.

Late last year the company announced a partnership with Happy Meal Prep and has been working relentlessly to perfect their temperature-controlled boxes to ensure safe delivery of MMG’s “healthier for you” food options. Customers can now order ready-made, prepared meals with options including Wraps, Bowls, Pastas and Salads. There are specific dietary categories as well including Keto and Gluten Free. After a minimum order of five meals, customers can order any quantity they desire to meet their meal prep needs. Customers can opt in for texts or emails to keep up to date on the brand’s latest offerings.

Mike Roper, CEO of Muscle Maker Grill, commented, “MuscleMakerPrep.com not only creates an additional revenue stream for the company but allows for us to reach broader audiences and new market segments. This is an expansion of our strategy to get healthier food options to consumers via non-traditional locations and methods. As an expression of gratitude to our loyal customer base, for a limited time, the company will offer 15% off all first time delivered meal plan orders. As of today, we will be able to serve the NY, NJ, and PA markets and are seeking to open more markets as we dive into 2021!”

About Muscle Maker Grill

Founded in 1995 in Colonia, New Jersey, Muscle Maker Grill features high quality, great tasting food, freshly prepared with proprietary recipes. The menu, created with the guest’s health in mind, is lean and protein based. It features all-natural chicken, grass fed steak, lean turkey, whole wheat pasta, wraps, bowls and more. It also offers a wide selection of fruit smoothies in a variety of assorted flavors, protein shakes and supplements. For more information on Muscle Maker Grill, visit www.musclemakergrill.com.

Forward-Looking Statements

This press release may include “forward-looking statements” pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as “should”, “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Muscle Maker, Inc does not undertake any duty to update any forward-looking statements except as may be required by law.

Contact:
Muscle Maker Grill Marketing:
[email protected]

Investor Relations:
[email protected]



PropTech Investment Corporation II Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing January 25, 2021

NEW YORK, Jan. 21, 2021 (GLOBE NEWSWIRE) — PropTech Investment Corporation II (NASDAQ: PTICU) (the “Company”) announced that, commencing January 25, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and warrants that are separated will trade on the Nasdaq Capital Market under the symbols “PTIC” and “PTICW,” respectively. Those units not separated will continue to trade on the Nasdaq Capital Market under the symbol “PTICU.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About PropTech Investment Corporation II

PropTech Investment Corporation II is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any stage of its corporate evolution or in any industry or sector, it intends to concentrate its efforts in identifying high quality business that provide technological innovation to the real estate industry, or PropTech. For more information, please visit proptechinvestmentcorp.com.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to the Company or its management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Cody Slach, Matt Glover
Gateway
(949) 574-3860
[email protected]



Reputation.com Now Available in Google Cloud Marketplace

The Global Leader in Reputation Experience Management Launches on the Google Cloud Marketplace to Turn Customer Interactions into Business Actions

REDWOOD CITY, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) — Reputation.com, the global leader in reputation experience management, today announced its platform services are now available in Google Cloud Marketplace. Customers worldwide can now access the Reputation.com platform as part of their tech stack, allowing businesses to transform feedback into a competitive advantage to enhance their customer experience.

In today’s world, a single keystroke can make or break a company’s reputation — which is why reputation management is a critical consideration among today’s top brands. Reputation.com delivers solutions that use customer feedback across all interactions to create customer experiences that delight and drive better business results. The power of the platform lies in the ability to combine unsolicited feedback data sources, such as business reviews and social media comments, with solicited feedback data, such as ratings and surveys, in one unified view. With Reputation.com, businesses can transform customer feedback into insights that fuel progress — all while building relationships between customers and communities.

“To deliver exceptional customer experiences, businesses today need to be able to quickly understand customer feedback and data. We’re excited that Reputation.com will deliver its extensive list of platforms and solutions on Google Cloud and we are happy to help them do so,” said Avanish Sahai, Vice President, Partnerships at Google Cloud. “With availability on the Google Cloud Marketplace, businesses of all sizes can deploy Reputation.com’s solutions, enabling organizations to leverage the global scale, security, and elasticity of Google Cloud.”


Organizations can now subscribe to Reputation.com
directly from Google Cloud Marketplace and begin actively managing their business listings, reviews, surveys and more. Reputation.com has been a strategic Google partner for several years, leveraging integrations with a number of Google technologies to provide best-in-class online reputation management solutions to companies of all sizes.

“We are excited to continue expanding upon our partnership with Google Cloud to not only better suit our customers, but also to ensure the Reputation.com platform is easily accessible to modern enterprises,” said Joe Fuca, chief executive officer at Reputation.com. “Joining Google Cloud Marketplace will allow us to continue delivering our best-in-class reputation management platform to today’s modern businesses, helping them turn their customer interactions into positive business action and increased revenue.”

About Reputation.com

Reputation.com pioneered the online reputation management (ORM) category and now extends its leadership position to include its award-winning Reputation Experience Management (RXM) platform that consistently delivers innovative, customer-driven solutions. The SaaS-based platform manages tens of millions of reviews and interactions across hundreds of thousands of customer touchpoints. The patented algorithms behind Reputation Score X are based on more than a decade of deep machine learning and data science expertise, providing businesses with a reliable index of brand performance that they can use to make targeted improvements. Reputation.com has over 250 integration partners, including Google, Facebook, Salesforce, J.D. Power, Amazon and Web.com, and helps businesses of all sizes across industries Get Found, Get Chosen and Get Better. To learn more, visit www.reputation.com.

Media Contacts

Kalie Marsch
Reputation.com
[email protected]

Brigit Valencia
BOCA Communications
360.597.4516
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d45acfdb-19b1-43cd-b3f2-463c7a16ecc7



Live Oak Acquisition Corp. II Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing January 25, 2021

Memphis, TN, Jan. 21, 2021 (GLOBE NEWSWIRE) — Live Oak Acquisition Corp. II (the “Company”) announced today that, commencing January 25, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock (“Class A Common Stock”) and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The shares of Class A common stock and warrants that are separated will trade on the New York Stock Exchange under the symbols “LOKB” and “LOKB WS,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “LOKB.U.” Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into shares of Class A Common Stock and Warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Live Oak Acquisition Corp. II

Live Oak Acquisition Corp.  II is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies it believes have significant growth prospects with the potential to generate attractive returns for its stockholders.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to the Company or its management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact: 

Andrea K. Tarbox
Chief Financial Officer
Live Oak Acquisition Corp. II
(203) 858-0934
[email protected] 



Biotalys Submits First Protein-Based Biocontrol Registration Package to the EPA

GHENT, Belgium and RESEARCH TRIANGLE PARK, N.C., Jan. 21, 2021 (GLOBE NEWSWIRE) — Today, Biotalys NV, a transformative food and crop protection company, announces that it has submitted its first protein-based biocontrol, Evoca™, to the Environmental Protection Agency (EPA) in the United States for approval. Pending EPA registration, this biocontrol will offer U.S. fruit and vegetable growers a new way to combat major diseases to maximize yields and extend the shelf life after harvest of produce with substantially lower residues.

“Biotalys is thrilled to have begun the EPA registration process for its first product. While Evoca targets diseases like Botrytis cinerea and powdery mildew, we are leveraging the flexibility of our technology platform to advance a broad pipeline of products with new modes of action that will safely and reliably address key crop pests and diseases across the food value chain,” commented Luc Maertens, COO of Biotalys.

Evoca will help growers effectively control key pathogens in the field, as well as in the food value chain to protect fruits and vegetables post harvest, extending shelf life and reducing decay and food loss. With its new mode of action and favourable safety profile, Evoca provides growers with additional rotational options to manage resistance in a more sustainable way.

The submission follows Biotalys’ successful completion of an extensive field product development program and regulatory studies on Evoca. More than 200 field and greenhouse trials globally demonstrated high consistency in effective control of key pathogens in fruit and vegetables crops. With this submission and pending regulatory approvals, Biotalys is on track to introduce Evoca to select regions in the U.S. market in late 2022.

Biotalys will proceed with international registrations on its own, maintaining full ownership of all rights. Aligned with the go-to-market strategy for Evoca, the submission in the United States will be followed by a submission in the European Union. Major agricultural markets in Latin America and Asia are in scope for future registrations.

Evoca™: Pending Registration. This product is not currently registered for sale or use in the United States and is not being offered for sale.

About Biotalys

Biotalys is a rapidly growing and transformative food and crop protection company developing a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Based on its groundbreaking technology platform, Biotalys has developed a broad pipeline of effective and safe candidate products that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Combining the high-performance characteristics and consistency of chemicals with the clean safety profile of biologicals, Biotalys goal is to provide ideal crop protection agents for both pre- and post-harvest applications. Based in the biotech cluster in Ghent, Belgium, Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and has raised €61 million ($66m USD) to date from specialist international investors. More information can be found on www.biotalys.com.

PDF available: http://ml.globenewswire.com/Resource/Download/c62d03a4-c6f2-4b53-a8d2-8883fcbfd403



Media Contacts:

Erica Camilo
Connexa Communications for Biotalys
T: +1 (610) 639 5644
E: [email protected]